Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer.

Clinical lung cancer - 1 Nov 2021

Merkhofer Cristina M, Eaton Keith D, Martins Renato G, Ramsey Scott D, Goulart Bernardo H L

Abstract excerpt

INTRODUCTION: The impact of clinical trial participation on overall survival is unclear. We hypothesized that enrollment in a therapeutic drug clinical trial is associated with longer overall survival in patients with metastatic non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: We linked electronic medical record and Washington State cancer registry data to identify patients with metastatic NSCLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Neoplasm Metastasis

Share to Patient Participation

Share to Registries

Share to Survival Analysis

Share to Washington

Source

Open in PubMed Open full text

Identifiers

PMID: 34059474
DOI: 10.1016/j.cllc.2021.04.003
PMCID: PMC8531178

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer.PMID 34059474Read ↗

Epidermal growth factor receptor positive lung cancer: The nontrial scenario.Semantic proximity Read ↗

Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.Semantic proximity Read ↗

Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations A case Study using Lung-MAP S1400ISemantic proximity Read ↗

Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.Semantic proximity Read ↗

Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.Semantic proximity Read ↗

Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer.Semantic proximity Read ↗

Transportability of patient outcomes from a US clinical trial to real-world populations - a case study using Lung-MAP S1400I (NCT02785952)Semantic proximity Read ↗

Chronological Age Is Not an Independent Determinant of Survival or Treatment Access in Metastatic Non–Small Cell Lung Cancer: A Real-World Cohort StudySemantic proximity Read ↗

Factors associated with time to EGFR TKI treatment in patients with non-squamous metastatic non-small-cell lung cancer.Semantic proximity Read ↗

Leveraging Longitudinal Patient-Reported Outcomes Trajectories to Predict Survival in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Impact of Waiting Times on Mortality in Advanced Stage Non-Small Cell Lung Cancer: A 10-Year Retrospective Cohort Study in Thailand.Semantic proximity Read ↗

Adequate Underrepresented Minority Representation in Cancer Trials: Evidence from an NCI-Designated Center in a Minority CountySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.